Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.72 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.72 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.72 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569747 | 0.84 | KDM4E (0.74) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| Chromocarb SCHEMBL432304 | 0.84 | KDM4E (1.00) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| Chromocarb SCHEMBL29355904 | 0.84 | KDM4E (1.00) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| SCHEMBL1532188 | 0.84 | KDM4E (0.74) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| SCHEMBL6386648 | 0.82 | CSNK2A2 (0.72) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| Chromocarb SCHEMBL29695542 | 0.82 | KDM4E (0.96) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| SCHEMBL12536148 | 0.82 | KDM4E (0.72) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| Chromocarb SCHEMBL28113935 | 0.82 | KDM4E (0.96) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| SCHEMBL13896163 | 0.82 | CSNK2A2 (0.72) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E | |
| Chromocarb SCHEMBL6633182 | 0.82 | KDM4E (0.96) | CSNK2A2CSNK2BCSNK2A1CSNK2A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020230037-A1 | ALTERNATE PROCESS FOR THE PREPARATION OF ENCEQUIDAR | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-11-19 | — | — | WO | claimed |
| US-12404267-B2 | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-09-02 | — | — | US | disclosed |
| US-20220135548-A1 | SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5- DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALT | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2022-05-05 | — | — | US | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020230037-A1 | ALTERNATE PROCESS FOR THE PREPARATION OF ENCEQUIDAR | DR. REDDY'S LABORATORIES LIMITED (IN) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020168144-A1 | SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(LH)- ISOQUINOLINYL)ETHYL] PHENYL }-2H-TETRAZOL-5-YL)-4,5-DIMETHOXYPHENYL] -4- OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALT | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2020-08-20 | — | — | WO | disclosed |
| US-20200190077-A1 | NEUROPROTECTIVE HYDRAZIDES | DAHL RUSSELL (US) | 2020-06-18 | — | — | US | disclosed |
| US-7772265-B2 | 2-oxadiazolechromone derivatives | MERCK PATENT GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772265-B2 | 2-oxadiazolechromone derivatives | MERCK PATENT GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-0625522-B1 | Benzopyran derivatives and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5741784-A | ADMINISTERING TO TREAT METABOLIC BONE DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-21 | — | — | US | disclosed |
| US-5684017-A | ANTIARTHRITIC AGENTS, RHEUMATIC DISEASES, ANTIDIABETIC AGENTS FOR INHIBITING INTERLOEUKINS | MERRELL PHARMACEUTICALS INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5604247-A | NEUROKININE ANTAGONIST | CIBA-GEIGY CORPORATION (US) | 1997-02-18 | — | — | US | disclosed |
| US-5580863-A | TREATMENT OF OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-03 | — | — | US | disclosed |
| EP-0731791-A1 | NOVEL BENZENESULFONYLIMINE DERIVATIVES AS INHIBITORS OF IL-1 ACTION | MERRELL PHARMACEUTICALS INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995014669-A1 | NOVEL BENZENESULFONYLIMINE DERIVATIVES AS INHIBITORS OF IL-1 ACTION | MERRELL PHARMACEUTICALS INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0625522-A1 | Benzopyran derivatives and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| CN-1073938-A | Novel benzenesulfonyl acrylate derivatives | GERDANG RICHARD CHEMICAL FACTO (HU) | 1993-07-07 | — | — | CN | disclosed |
| WO-1993012079-A1 | NOVEL PHENYLSULFONYLACRYLATE ESTER DERIVATIVES | RICHTER GEDEON VEGYE^´SZETI GYÁR RT. (HU) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | CSNK2A2 710/4885CSNK2B 613/4885CSNK2A1 687/4885 |
| US-20200190077-A1 | NEUROPROTECTIVE HYDRAZIDES | PINK1, UCHL1, SIRT1 | CSNK2A2 1307/4885CSNK2B 1111/4885CSNK2A1 1351/4885 |
| US-20220135548-A1 | SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5- DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALT | MC5R, HTR2A, MC2R | CSNK2A2 2725/4885CSNK2B 3188/4885CSNK2A1 2922/4885 |
| US-12404267-B2 | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt | MC5R, HTR2A, MC2R | CSNK2A2 2725/4885CSNK2B 3188/4885CSNK2A1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.